EMHTF - Emerald Health Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2000
0.0000 (0.00%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.2000
Open0.2000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1872 - 0.2200
52 Week Range0.0700 - 2.7200
Volume342,325
Avg. Volume416,109
Market Cap38.425M
Beta (5Y Monthly)0.80
PE Ratio (TTM)N/A
EPS (TTM)-0.1290
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Emerald Health Therapeutics Terminates Land Sub-lease and Outdoor Cultivation Agreements

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announces that it has terminated certain related party agreements pertaining to its cannabis cultivation operation in Metro Vancouver. Previously existing rights and continuing usage of the land and its cultivation operation in Metro Vancouver are unaffected by these terminations. As previously announced on October 4, 2019, Emerald entered into a sublease agreement ("Sublease Agreement") and a cultivation agreement ("Cultivation Agreement") with Emerald Health Sciences Inc. ("EHS"), a control person of Emerald.

  • GlobeNewswire

    Emerald Health Therapeutics Announces Pure Sunfarms’ Initial Cultivation and Sales License for Second Greenhouse

    VANCOUVER, British Columbia, May 25, 2020 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announces that its joint venture for large-scale, low-cost,.

  • GlobeNewswire

    Emerald Announces $2.1 Million Prospectus Sale

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), has entered into a binding term sheet with a single Canadian institutional accredited investor (the “Investor”) under which the Investor has agreed, subject to certain customary conditions, to purchase 11,351,351 units of Emerald (each, a "Unit") at a price of $0.185 per Unit for total gross proceeds of $2,100,000 (the "Offering"). Each Unit will consist of one common share of Emerald (each, a "Common Share") and one common share purchase warrant (each, a "Warrant").

  • GlobeNewswire

    Emerald Health Therapeutics Reports Pure Sunfarms First Quarter 2020 Financial Results

    During the three months ended March 31, 2020, Pure Sunfarms made important strides in growing its cannabis retail sales to provincial distributors, increasing revenue and volume in the retail market by 118% and 179%, respectively, over the fourth quarter of 2019. It continued to build market share in Ontario through the end of April, introduced competitive new product formats, and added new provincial markets in its ongoing market expansion effort. In achieving these steps, Pure Sunfarms achieved its fifth consecutive quarter of net income and sixth consecutive quarter of positive EBITDA.

  • GlobeNewswire

    Emerald Health Therapeutics Reports Year-end and Fourth Quarter 2019 Financial Results and Provides Corporate Update

    VANCOUVER, British Columbia, May 14, 2020 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) reported financial results for the quarter and year ended.

  • GlobeNewswire

    Emerald Health Therapeutics to Host 2019 Fourth Quarter and Year End Financial Results Conference Call on Thursday, May 14, 2020 at 10:30 AM ET

    VANCOUVER, May 08, 2020 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that, further to its news release on April 29th, Emerald will.

  • Introducing Emerald Health Therapeutics (CVE:EMH), The Stock That Collapsed 95%
    Simply Wall St.

    Introducing Emerald Health Therapeutics (CVE:EMH), The Stock That Collapsed 95%

    It's nice to see the Emerald Health Therapeutics, Inc. (CVE:EMH) share price up 13% in a week. But that hardly...

  • GlobeNewswire

    Emerald Health Therapeutics Extends Dates for Filing Financial Statements

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announces that as a result of the COVID-19 pandemic, Emerald, as well as its auditors and filing agents, have followed the recommendations of local health authorities and temporarily closed their offices, having employees work remotely to minimize their exposure risk. In addition, the United States Securities and Exchange Commission (“SEC”) has issued an order under Section 36 of the Exchange Act (Release Nos.

  • GlobeNewswire

    Emerald Health Therapeutics to Launch Rapid Onset Nanoemulsion Cannabinoid & Terpene Product Line, Providing Consumers with Enhanced Immediacy and Control

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) is announcing its new nanoemulsion-based Fast Action Spray product line, an important step in Emerald’s Cannabis 2.0 strategy and a unique offering in the Canadian cannabis marketplace. The product line will consist of CBD and THC cannabinoids mixed with specific terpenes and flavorings. Emerald has chosen to add specific all-natural terpenes to its nanoemulsion product line: myrcene has been shown to have anti-inflammatory, analgesic, and anxiolytic properties; limonene has been shown to have anti-inflammatory, analgesic, antioxidant, antidepressant and immunostimulating attributes*.

  • GlobeNewswire

    Emerald Health Therapeutics Proposes to Amend Warrant Terms

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announces that it intends to amend the terms of certain common share purchase warrants originally issued on September 9, 2019 (the “Warrants”). An aggregate of 12,500,000 Warrants were initially issued at an exercise price of $2.00 per common share of Emerald (each, a "Common Share") in connection with a $25,000,000 convertible debenture financing. 6,250,000 Warrants will have an exercise price of $0.17 per Common Share (the "$0.17 Warrants").

  • GlobeNewswire

    Emerald Health Therapeutics Releases First Harvest of Premium Cannabis from its 100%-Owned Cultivation Facility in Richmond, BC

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has announced that the first shipment of its own unique version of the cannabis strain, Chemdog, from its 100%-owned Richmond facility is now available through the BC Liquor Distribution Board’s online site and will become available in certain licensed cannabis retail stores in British Columbia. Emerald’s version of Chemdog, a sativa-dominant hybrid strain with 19-25% THC and 0-1% CBD, is the first of five unique strains that Emerald is growing and harvesting in its new Richmond, BC, operation.

  • GlobeNewswire

    Emerald Health Therapeutics’ Pure Sunfarms JV Expands Credit Facility with Existing Lender by up to $59M and Completes Additional $8M Financing

    VANCOUVER, British Columbia, April 03, 2020 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announced that its Pure Sunfarms (“PSF”) joint venture.

  • ACCESSWIRE

    Emerald Health Therapeutics' Pure Sunfarms JV Expands Credit Facility with Existing Lender by up to $59M

    VANCOUVER, BC / ACCESSWIRE / March 31, 2020 / Emerald Health Therapeutics, Inc. ("Emerald") (TSXV:EMH; OTCQX:EMHTF) announced that its Pure Sunfarms ("PSF") joint venture has expanded ...

  • ACCESSWIRE

    Emerald Health Therapeutics’ Joint Venture, Pure Sunfarms, Reports Positive Operating and Financial Growth in 2019, with Significant EBITDA Performance of $54.1 Million

    VANCOUVER, BC / ACCESSWIRE / March 31, 2020 / Emerald Health Therapeutics, Inc. ("Emerald") (TSXV:EMH; OTCQX:EMHTF) has provided audited financial results for the fourth quarter and year of 2019 for its British Columbia-based joint venture, Pure Sunfarms (PSF). Net sales, consisting entirely of dried cannabis, for the year and fourth quarter of 2019 were $82.8 million and $12.1 million, respectively, compared to $4.9 million and $4.7 million. "All-in" cost of cultivation (including depreciation) for the year was $0.78 per gram and for the fourth quarter was $0.66 per gram.

  • ACCESSWIRE

    Emerald Health Therapeutics’ Pure Sunfarms JV Receives Health Canada Approval for State-of-the-Art Processing Centre

    VANCOUVER, BC / ACCESSWIRE / March 23, 2020 / Emerald Health Therapeutics, Inc. ("Emerald") (EMH.V)(EMHTF) announced that its Pure Sunfarms (PSF) joint venture has received approval from Health Canada for the final components of its 65,000 square foot state-of-the-art processing center. This additional processing space enables PSF to further optimize processing operations and throughput, realize additional production cost efficiencies, expand product offerings, and further elevate the quality of its products. "The approval of this additional processing space enables Pure Sunfarms to enhance our operations and quality processes to further support our commitment to providing our customers with high-quality products at a great price," said Mandesh Dosanjh, President and CEO, Pure Sunfarms.

  • GlobeNewswire

    Emerald Health Therapeutics Signs LOI with Sigma Analytical Services

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) (“Emerald”) has signed a letter of intent under which Sigma Analytical Services Inc. (“Sigma”), a full-service GMP-compliant testing laboratory for cannabis, hemp, and derived products, may acquire Emerald’s Avalite cannabis analytical testing operation. Execution of definitive agreements is subject to due diligence and board approval of both companies and is expected to occur on or before April 19, 2020.

  • GlobeNewswire

    Emerald Health Therapeutics, Pure Sunfarms, and Village Farms Complete Settlement of All Disputes

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that, further to its news release dated March 3, 2020, all transactions contemplated by the settlement agreement (the "Settlement Agreement") among Emerald, Village Farms International, Inc. ("Village Farms") and Pure Sunfarms Corp. ("PSF" and together with Emerald and Village Farms, the "Parties") regarding disputes between the Parties have been completed. As such, the arbitration process involving the Parties has been discontinued.

  • GlobeNewswire

    Emerald Health Therapeutics, Pure Sunfarms, and Village Farms Settle All Disputes

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has entered into a settlement agreement (the "Settlement Agreement") with Village Farms International, Inc. ("Village Farms") and Pure Sunfarms Corp. ("PSF," and together with Emerald and Village Farms, the "Parties") regarding disputes between the Parties (the "Settlement"). On completion of the Settlement the arbitration process involving the Parties will be discontinued.

  • GlobeNewswire

    Emerald Health Therapeutics’ Pure Sunfarms Joint Venture Makes First Cannabis Shipment to Alberta

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announced that its 50%-owned joint venture for large-scale, low-cost, quality cannabis production, Pure Sunfarms Corp. (“Pure Sunfarms” or “PSF”), has completed its first shipment of cannabis under its supply agreement with Alberta Gaming, Liquor & Cannabis (AGLC). Pure Sunfarms’ recreational adult-use cannabis products will be available on Alberta’s only legal online store (AlbertaCannabis.org) in the first week of March and can be purchased by the province’s licensed private sector retailers. The AGLC is the wholesaler to private retailers and the only authorized online retailer in Alberta.

  • GlobeNewswire

    Emerald Health Therapeutics Closes Final Tranche Prospectus Sale

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has closed the final tranche of its $3,000,000 prospectus offering (the “Offering”), announced in its news release dated January 6, 2020. Pursuant to this final closing, Emerald has issued an aggregate of 2,748,276 units of Emerald (each, a "Unit") at a price of $0.29 per Unit for total gross proceeds of $797,000. The initial tranche of the Offering closed on February 6, 2020 for gross proceeds of $2,203,000.

  • GlobeNewswire

    Emerald Health Therapeutics Closes $2.2 Million Prospectus Sale

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has closed the first tranche of its $3,000,000 prospectus offering (the “Offering”) announced in its news release dated January 6, 2020. Pursuant to this initial closing, Emerald has issued an aggregate of 7,596,551 units of Emerald (each, a "Unit") at a price of $0.29 per unit for total gross proceeds of $2,203,000. Emerald will issue the remaining 2,748,276 Units, for gross proceeds of $797,000, upon receipt of all necessary approvals, including the approval of the TSX Venture Exchange and applicable securities regulatory authorities.

  • Should You Be Concerned About Emerald Health Therapeutics, Inc.'s (CVE:EMH) Historical Volatility?
    Simply Wall St.

    Should You Be Concerned About Emerald Health Therapeutics, Inc.'s (CVE:EMH) Historical Volatility?

    If you own shares in Emerald Health Therapeutics, Inc. (CVE:EMH) then it's worth thinking about how it contributes to...

  • GlobeNewswire

    Emerald Health Therapeutics Closes Shares for Debt Financing

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), is pleased to announce that it has closed its previously announced shares for debt financing. Further to its news release dated January 27, 2020, Emerald has settled $2,816,963 (the "Debt") of the aggregate debt owed by Emerald to Emerald Health Sciences Inc. ("Sciences"), a control person of Emerald, in exchange for the issuance of 9,713,666 common shares of Emerald (each, a "Debt Share") at a deemed value of $0.29 per Debt Share (the "Debt Settlement"). The Debt consists of: (i) $794,182 owed to Sciences pursuant to a previously disclosed loan agreement between the parties; and (ii) $2,022,781 owed to Sciences pursuant to trades payable.

  • GlobeNewswire

    Emerald Health Therapeutics Provides Update on Financing Transactions

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today provided an update on a previously announced shares for debt transaction. Further to its news release dated December 16, 2019, Emerald will be settling $2,816,963 (the "Debt") of the aggregate debt owed by Emerald to Emerald Health Sciences Inc. ("Sciences"), a control person of Emerald. Emerald will satisfy the Debt by issuing 9,713,666 common shares of Emerald (each, a "Debt Share") at a deemed value of $0.29 per Debt Share (the "Debt Settlement").

  • GlobeNewswire

    Emerald Health Therapeutics’ Joint Venture Partner Withdraws Purported $5.94 Million Investment in Pure Sunfarms

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that Village Farms International, Inc. ("Village Farms") has withdrawn its attempt to make an unsupported  additional equity contribution in their joint venture, Pure Sun Farms Corp. (“PSF”). Village Farms has rescinded the attempt and has requested and received a refund of the $5.94 million it advanced to PSF in November 2019. The previously announced arbitration proceedings between the parties remain in process with respect to Emerald’s right to set-off a $5.94 million payment owed by Emerald to PSF against a portion of the more than $13 million currently owed by PSF to Emerald under its shareholder loan.